Irritable bowel syndrome (IBS) affects 10-15% of people around the world. It is a chronic gastrointestinal disorder with symptoms including abdominal pain, discomfort, diarrhoea and constipation. Most medications are used to treat these symptoms independently of each other and few treatments relieve the symptoms of IBS as a whole (Drossman et al. 2010). Studies have demonstrated that there is a substantial, clinically significant placebo effect for IBS. This then led Harvard researchers to investigate if using placebo for IBS could be both ethical and effective.
Did you know that placebo effects and nocebo effect can be evoked without a placebo; or how about the unspoken ethics code when it comes to prescribing placebos? In a talk by Dr Luana Colloca we learn about the conflicts, ethics and future use of the placebo effect in clinical practice. Here, we summarise some of the key ideas in Dr Colloca's talk.